Advagene Biopharma Co (ROCO:6709) Change In Working Capital : NT$5.08 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Change In Working Capital?

Advagene Biopharma Co's change in working capital for the quarter that ended in Jun. 2024 was NT$3.51 Mil.

Advagene Biopharma Co's change in working capital for the fiscal year that ended in Dec. 2023 was NT$2.50 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Advagene Biopharma Co Change In Working Capital Historical Data

The historical data trend for Advagene Biopharma Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Change In Working Capital Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

36.28

31.65

17.68

-2.70

2.50

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Working Capital	Get a 7-Day Free Trial											-3.26	0.56	0.92	1.57	3.51

Advagene Biopharma Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$5.08 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Advagene Biopharma Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co Headlines

No Headlines